Free Trial
→ Elon Musk about to bankrupt Amazon, Microsoft & Google? (From Brownstone Research) (Ad)tc pixel

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Compare
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
CCXI
Churchill Capital Corp XI
$10.69
+15.1%		$11.88
$8.00
▼
$19.69
$762.80M1.221.92 million shs4.52 million shs
HUTCHMED (China) Limited Sponsored ADR stock logo
HCM
HUTCHMED
$13.08
-1.4%		$13.68
$9.77
▼
$16.33
$2.32B0.344,031 shs28,849 shs
The 7 Hottest IPO Stories of 2026 Cover
The 7 Hottest IPO Stories of 2026

MarketBeat just released its list of the 7 hottest IPOs expected to hit Wall Street in 2026. See which companies are preparing to go public and why investors are watching closely.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
CCXI
Churchill Capital Corp XI
+15.07%+4.39%-10.84%-32.89%+1,068,999,900.00%
HUTCHMED (China) Limited Sponsored ADR stock logo
HCM
HUTCHMED
-1.43%-5.22%-7.89%+13.25%-14.57%
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
CCXI
Churchill Capital Corp XI
$10.69
+15.1%		$11.88
$8.00
▼
$19.69
$762.80M1.221.92 million shs4.52 million shs
HUTCHMED (China) Limited Sponsored ADR stock logo
HCM
HUTCHMED
$13.08
-1.4%		$13.68
$9.77
▼
$16.33
$2.32B0.344,031 shs28,849 shs
The 7 Hottest IPO Stories of 2026 Cover
The 7 Hottest IPO Stories of 2026

MarketBeat just released its list of the 7 hottest IPOs expected to hit Wall Street in 2026. See which companies are preparing to go public and why investors are watching closely.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
CCXI
Churchill Capital Corp XI
+15.07%+4.39%-10.84%-32.89%+1,068,999,900.00%
HUTCHMED (China) Limited Sponsored ADR stock logo
HCM
HUTCHMED
-1.43%-5.22%-7.89%+13.25%-14.57%
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
CCXI
Churchill Capital Corp XI
1.00
SellN/AN/A
HUTCHMED (China) Limited Sponsored ADR stock logo
HCM
HUTCHMED
2.67
Moderate Buy$14.8713.66% Upside

Current Analyst Ratings Breakdown

Latest CCXI and HCM Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
10/20/2026
HUTCHMED (China) Limited Sponsored ADR stock logo
HCM
HUTCHMED
Weiss Ratings logo
Weiss Ratings
Subscribe to MarketBeat All Access to unlock brokerage rankings
UpgradeSell (D) ➝ Sell (D+)
9/8/2026
HUTCHMED (China) Limited Sponsored ADR stock logo
HCM
HUTCHMED
HSBC Holdings plc logo
HSBC
Subscribe to MarketBeat All Access to unlock brokerage rankings
UpgradeHold ➝ Buy
9/3/2026
HUTCHMED (China) Limited Sponsored ADR stock logo
HCM
HUTCHMED
Daiwa Securities Group Inc. logo
Daiwa Securities Group
Subscribe to MarketBeat All Access to unlock brokerage rankings
UpgradeHold ➝ Buy
8/18/2026
CCXI
Churchill Capital Corp XI
Weiss Ratings logo
Weiss Ratings
Subscribe to MarketBeat All Access to unlock brokerage rankings
UpgradeSell (E) ➝ Sell (D)
(Data available from 11/4/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
CCXI
Churchill Capital Corp XI
$37.20M20.51N/AN/AN/A∞
HUTCHMED (China) Limited Sponsored ADR stock logo
HCM
HUTCHMED
$548.51M4.16$2.66 per share4.92$7.17 per share1.82
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
CCXI
Churchill Capital Corp XI
N/A-$1.89N/AN/AN/AN/AN/AN/AN/A
HUTCHMED (China) Limited Sponsored ADR stock logo
HCM
HUTCHMED
$456.91MN/AN/A59.45N/AN/AN/AN/AN/A
CompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive Growth
CCXI
Churchill Capital Corp XI
N/AN/AN/AN/AN/A
HUTCHMED (China) Limited Sponsored ADR stock logo
HCM
HUTCHMED
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
CCXI
Churchill Capital Corp XI
N/AN/AN/A
HUTCHMED (China) Limited Sponsored ADR stock logo
HCM
HUTCHMED
0.06
5.64
5.50

Institutional Ownership

CompanyInstitutional Ownership
CCXI
Churchill Capital Corp XI
81.09%
HUTCHMED (China) Limited Sponsored ADR stock logo
HCM
HUTCHMED
8.82%

Insider Ownership

CompanyInsider Ownership
CCXI
Churchill Capital Corp XI
8.30%
HUTCHMED (China) Limited Sponsored ADR stock logo
HCM
HUTCHMED
3.60%
CompanyEmployeesShares OutstandingFree FloatOptionable
CCXI
Churchill Capital Corp XI
271.36 millionN/AOptionable
HUTCHMED (China) Limited Sponsored ADR stock logo
HCM
HUTCHMED
1,796174.47 million168.19 millionOptionable

Recent News About These Companies

Hutchmed Advances ORPATHYS-TAGRISSO Lung Cancer Treatment Filings in Europe, Japan
November 2 at 6:07 PM  |  finance.yahoo.comhttps://finance.yahoo.com/healthcare/articles/hutchmed-advances-orpathys-tagrisso-lung-092031177.html
HUTCHMED Announces Regulatory Filings Accepted for Review for ORPATHYS® plus TAGRISSO® in MET-Driven EGFR-Mutated Lung Cancer in Europe and Japan
November 1 at 7:00 PM  |  globenewswire.comhttps://www.globenewswire.com/news-release/2026/11/02/3392807/0/en/hutchmed-announces-regulatory-filings-accepted-for-review-for-orpathys-plus-tagrisso-in-met-driven-egfr-mutated-lung-cancer-in-europe-and-japan.html
HUTCHMED (NASDAQ:HCM) Share Price Crosses Below Two Hundred Day Moving Average - Here's What Happened
October 31, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/price-hutchmed-nasdaq-hcm-share-price-crosses-below-two-hundred-day-moving-average-heres-what-happened-2026-10-31/
Hutchmed Says Drug Candidate for Autoimmune Bleeding Disorder Gets FDA's Orphan Drug Designation
October 29, 2026  |  finance.yahoo.comhttps://finance.yahoo.com/healthcare/articles/hutchmed-says-drug-candidate-autoimmune-094209522.html
HUTCHMED Announces Sovleplenib Granted US FDA Orphan Drug Designation for Primary Immune Thrombocytopenia
October 28, 2026  |  globenewswire.comhttps://www.globenewswire.com/news-release/2026/10/29/3390878/0/en/hutchmed-announces-sovleplenib-granted-us-fda-orphan-drug-designation-for-primary-immune-thrombocytopenia.html
Bank of America Securities Keeps Their Buy Rating on HUTCHMED (HCM)
October 27, 2026  |  theglobeandmail.comhttps://www.theglobeandmail.com/investing/markets/markets-news/Tipranks/8471253/bank-of-america-securities-keeps-their-buy-rating-on-hutchmed-hcm/
Save the Date: HUTCHMED to Host Expert Insights Event on Recent Savolitinib Clinical Data in Non-Small Cell Lung Cancer
October 26, 2026  |  globenewswire.comhttps://www.globenewswire.com/news-release/2026/10/27/3388651/0/en/save-the-date-hutchmed-to-host-expert-insights-event-on-recent-savolitinib-clinical-data-in-non-small-cell-lung-cancer.html
Hutchmed, AstraZeneca Say Potential Metastatic Non-Small Cell Lung Cancer Treatment Reduces Disease Progress
October 26, 2026  |  finance.yahoo.comhttps://finance.yahoo.com/healthcare/articles/hutchmed-astrazeneca-potential-metastatic-non-093222509.html
HUTCHMED Highlights SANOVO Phase III Data for ORPATHYS® plus TAGRISSO® in First-Line EGFR-Mutated Lung Cancer Presented at ESMO Congress 2026
October 26, 2026  |  globenewswire.comhttps://www.globenewswire.com/news-release/2026/10/26/3387851/0/en/hutchmed-highlights-sanovo-phase-iii-data-for-orpathys-plus-tagrisso-in-first-line-egfr-mutated-lung-cancer-presented-at-esmo-congress-2026.html
HUTCHMED Highlights SAFFRON Global Phase III Data Presented at ESMO Congress 2026 and Simultaneously Published in The New England Journal of Medicine
October 25, 2026  |  globenewswire.comhttps://www.globenewswire.com/news-release/2026/10/26/3387782/0/en/hutchmed-highlights-saffron-global-phase-iii-data-presented-at-esmo-congress-2026-and-simultaneously-published-in-the-new-england-journal-of-medicine.html
HUTCHMED Announces Closing of KRAS-EGFR-Antibody Conjugate Therapy License to GSK Outside China
October 20, 2026  |  globenewswire.comhttps://www.globenewswire.com/news-release/2026/10/21/3385054/0/en/hutchmed-announces-closing-of-kras-egfr-antibody-conjugate-therapy-license-to-gsk-outside-china.html
HUTCHMED (NASDAQ:HCM) Shares Gap Up - Time to Buy?
October 20, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/price-hutchmed-nasdaq-hcm-shares-gap-up-time-to-buy-2026-10-20/
HUTCHMED (AIM:HCM) Stock Looks Expensive Relative To Current Earnings
October 18, 2026  |  finance.yahoo.comhttps://finance.yahoo.com/markets/stocks/articles/hutchmed-aim-hcm-stock-looks-041753501.html
HUTCHMED (China) Limited Sponsored ADR (NASDAQ:HCM) Stock Has Consensus Price Target of $14.87 According to Analysts
October 16, 2026  |  defenseworld.netD
HUTCHMED (China) Limited Sponsored ADR (NASDAQ:HCM) Stock Rated "Moderate Buy" by Sell-Side Brokerages
October 13, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/consensus-hutchmed-china-limited-sponsored-adr-nasdaq-hcm-stock-rated-moderate-buy-by-sell-side-brokerages-2026-10-13/
How Investors May Respond To HUTCHMED (China) (AIM:HCM) US NDA For ORPATHYS–TAGRISSO Lung Cancer Combo
October 12, 2026  |  finance.yahoo.comhttps://finance.yahoo.com/healthcare/articles/investors-may-respond-hutchmed-china-031648737.html
Citic Securities Remains a Buy on HUTCHMED (China) (HCM)
October 5, 2026  |  theglobeandmail.comhttps://www.theglobeandmail.com/investing/markets/stocks/HCM/pressreleases/4525963/citic-securities-remains-a-buy-on-hutchmed-china-hcm/
ADP Warns of Cooling Labor Market While Its Own Business Feels the Chill
October 3, 2026  |  247wallst.comhttps://247wallst.com/investing/2026/10/03/adp-warns-of-cooling-labor-market-while-its-own-business-feels-the-chill/?utm_source=snapi
AstraZeneca files US FDA application for HUTCHMED lung cancer drug combination
September 28, 2026  |  reuters.comhttps://www.reuters.com/business/healthcare-pharmaceuticals/astrazeneca-files-us-fda-application-hutchmed-lung-cancer-drug-combination-2026-09-29/
HUTCHMED Announces Submission of US NDA for ORPATHYS® plus TAGRISSO® in MET-Driven EGFR-Mutated Lung Cancer
September 28, 2026  |  globenewswire.comhttps://www.globenewswire.com/news-release/2026/09/29/3370345/0/en/hutchmed-announces-submission-of-us-nda-for-orpathys-plus-tagrisso-in-met-driven-egfr-mutated-lung-cancer.html
HUTCHMED Starts Global Phase 1 Trial Of KRAS-EGFR Therapy HMPL-A830 In Solid Tumors
September 28, 2026  |  rttnews.comhttps://www.rttnews.com/3694124/hutchmed-starts-global-phase-1-trial-of-kras-egfr-therapy-hmpl-a830-in-solid-tumors.aspx

New MarketBeat Followers Over Time

Media Sentiment Over Time

Churchill Capital Corp XI NASDAQ:CCXI

$10.69 +1.40 (+15.07%)
Closing price 11/3/2026 04:00 PM Eastern
Extended Trading
$11.34 +0.65 (+6.08%)
As of 11/3/2026 07:59 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Churchill Capital Corp XI is a blank check company.

HUTCHMED stock logo

HUTCHMED NASDAQ:HCM

$13.08 -0.19 (-1.43%)
Closing price 11/3/2026 04:00 PM Eastern
Extended Trading
$13.14 +0.06 (+0.44%)
As of 11/3/2026 04:08 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

HUTCHMED (China) Ltd. is a holding company, which engages in the research and development, manufacture, and sale of pharmaceuticals and health-oriented consumer products. It operates through the Oncology/Immunology and Other Ventures segments. The Oncology/Immunology segment includes the discovery, development, and commercialization of targeted therapies and immunotherapies for the treatment of cancer and immunological diseases. The Other Ventures segment involves the other commercial businesses which include the sales, marketing, manufacture, and distribution of prescription drugs and healthcare products. The company was founded on December 18, 2000 and is headquartered in Hong Kong.

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

Stock Lists
Low Priced Stocks
Stocks By Exchange
Latest Stock Ideas